The clozapine handbook
Series: Stahl's handbooks | Cambridge medicinePublication details: Cambridge : Cambridge University Press, 2019.Description: xi, 317pISBN:- 9781108447461
- WM 402.
Item type | Home library | Class number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|
Book | Oxleas NHS Foundation Trust Knowledge Services Librarians Office | WM 402 MEY (Browse shelf(Opens below)) | Available | x02081 | ||
Book | Oxleas NHS Foundation Trust Knowledge Services Librarians Office | WM 402 MEY (Browse shelf(Opens below)) | Available | x02083 | ||
Book | Oxleas NHS Foundation Trust Knowledge Services Librarians Office | WM 402 MEY (Browse shelf(Opens below)) | Available | x02082 | ||
Book | South London and Maudsley Trust Library Shelves | WM 402 MEY (Browse shelf(Opens below)) | Available | 023415 | ||
Book | South London and Maudsley Trust Library Shelves | WM 402 MEY (Browse shelf(Opens below)) | Available | 023390 |
Browsing South London and Maudsley Trust Library shelves, Shelving location: Shelves Close shelf browser (Hides shelf browser)
WM 402 ING Psychopharmacology for helping professionals : | WM 402 JON Nurse prescribing in mental health | WM 402 MEY The clozapine handbook | WM 402 MEY The clozapine handbook | WM 402 MIN Psychodynamic psychopharmacology : caring for the treatment-resistant patient | WM 402 MON The myth of the chemical cure : a critique of psychiatric drug treatment / | WM 402 MUT Mental health medicines management for nurses |
Copyright date is 2020 but actually published in 2019.
Preface
1. Initiating Clozapine
2. Understanding hematologic monitoring and benign ethnic neutropenia
3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels
4. Managing constipation
5. Managing sialorrhea
6. Managing sedation, orthostasis and tachycardia
7. Managing metabolic adverse effects
8. Managing seizure risk and stuttering
9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy
10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities
11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder
12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis
13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients
14. Discontinuing clozapine and management of cholinergic rebound
15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution
Index.
Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.
There are no comments on this title.